Cantourage Sets New Revenue Record in April 2025

In April 2025, Cantourage Group SE, a major player in the European medical cannabis market, achieved a record monthly revenue of EUR 11.1 million. This figure surpasses the previous month's record of EUR 10.7 million, highlighting the company's robust growth trajectory.

The increase reflects sustained demand for Cantourage's products, particularly in Germany, the United Kingdom, and Poland. The firm is well-positioned to meet this demand through enhanced product availability, a stable supply chain, and heightened processing capacities in Germany and Portugal.

Founded in 2019, Cantourage collaborates with over 60 cannabis growers globally. It provides products across dried flowers, extracts, dronabinol, and cannabidiol segments. Since November 2022, Cantourage has been listed on the Frankfurt Stock Exchange.